adipiplon

Small moleculeexperimental

Adipiplon is an anxiolytic drug developed by Neurogen Corporation. It has similar effects to benzodiazepine drugs, but is structurally distinct and classed as a nonbenzodiazepine anxiolytic. — Wikipedia

Clinical trial activity

1 trials · 1 clinical orgs · 0 marketing orgs

Phase 1

Phase 2

Phase 3

Phase 4

Earliest trial started May 1, 2008 (NCT00683436)

Timeline

2000s

Jan 1, 2008
Earliest Phase 2 Sponsor(trial)

Indications

Studied for

Sleep Initiation and Maintenance Disorders · Phase 2

Mechanism of action

GABA-A receptor; anion channelPARTIAL AGONIST
GABA-A receptor; anion channel partial agonist
Benzodiazepine site

Chemistry & pharmacology

Loading structure…

SMILES

CCCc1c(Cn2ccnc2-c2ncccc2F)ncn2nc(C)nc12

Mol. weight: 351.39 g/mol
Lipinski Ro5: Pass
Rule of 3: No
Chirality: Achiral Molecule
Inorganic: No
Polymer: No

Oral

Parenteral

Topical

Sources

WikipediaAdipiplon ↗
ChEMBLCHEMBL2103791 ↗

Also known as

7-((2-(3-fluoropyridin-2-yl)-1h-imidazol-1-yl)methyl)-2-methyl-8-propyl-(1,2,4)triazolo(1,5-c)pyrimidine
adipiplon
adipiplon
adipiplon
adipiplon
adipiplon
apiplon
apiplon
ng2-73
ng2-73
ng2-73

Clinical trials

NCT ID	Phase	Start date	Sponsor(s)
NCT00683436	Phase 2	May 1, 2008	Neurogen Corporation

Showing 1 of 1 trials

Page 1 / 1

Organizations

Research & Development (1)

Organization	Org type	Trials	As lead sponsor	Phases	Earliest year
Neurogen Corporation	For profit	1	1	1	2008

1 organizations

Page 1 / 1